Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 March 2025 | Story Andre Damons | Photo Andre Damons
Dr Willem Daffue
Dr Willem Daffue, veterinarian, adventurer, explorer, and conservationist, delivered the first plenary keynote address on the first day of the Southern African Mountain Conference (SAMC2025).

Africa’s mountains are being destroyed – not by global warming, but by small-scale farming caused by overpopulation on the continent.

This is according to Dr Willem Daffue, veterinarian, adventurer, explorer, and conservationist who delivered the first plenary keynote address on the first day of the Southern African Mountain Conference (SAMC2025). The conference, which follows a highly successful first conference in 2022, is currently taking place at the Champagne Sports Resort. It ends on 20 March 2025.

Comparing photos that he took 40 years ago in Ethiopia and the Democratic Republic of the Congo with more recent photos, Dr Daffue painted a dire picture of the future of Africa’s mountains and the unique animals found there.

Overpopulation

Dr Daffue works for the Himalayan Wildlife Project, tracks bears in the Karakoram Mountains, documents and photographs endangered species on a global level – such as the Javan rhino and Sumatran rhino. He is also involved in the Giraffe Project of the University of the Free State (UFS).

“Global warming has not yet affected Africa’s mountains. The rainfall in these areas actually increased. So has the population. Humans are destroying the mountains. The small-scale farmers have caused the most destruction. The reason for this is overpopulation.”

“Overpopulation is forcing people to invade national parks where they start farming for survival. These people are poor, uneducated, and is dependent on aid. All the animals in these areas are critically endangered.”

In his presentation, Dr Daffue talked about the Erta Ale, an active basaltic shield volcano in the Afar region of northeastern Ethiopia, the Simien Mountains in northern Ethiopia, as well as the Bale Mountains in the highlands of Ethiopia – with unique animals exclusive to the areas, including the wild ass, baboons, beisa oryx, Soemmerring's gazelle, Walia ibex, the golden jackal, and the Simien wolf.

Endangered animals

“Almost all the animals found in Ethiopia are endangered. It is the total destruction of nature. Only 4% of all mammals are still wild animals. 96% off all mammals on earth are humans and domesticated animals, and 70% of all birds on earth are chickens.”

“So, we are going to lose it. We are already past a point where we could save some of the animals and nature; it is an emergency but if we wake up now, we might still have a few things to save,” said Dr Daffue.

The answer is to curb the population growth, to educate the people, and to lift them out of poverty. Which is extremely difficult to do.

According to Dr Daffue, a conference such as the SAMC is extremely important, as it brings together different role players, including academics, researchers, communities, and policy makers. It helps in making plans, sharing knowledge, and getting policies out to people, the decision makers.

The conference

The Southern African Mountain Conference – conceptualised by the UFS Afromontane Research Unit (ARU), the African Mountain Research Foundation (AMRF), and Global Mountain Safeguard Research (GLOMOS) as a joint initiative between Eurac Research and the UNU Institute for Environment and Human Security – is unique, as it seeks to integrate the science, policy, and practitioner sectors for sustainable interventions in Southern African mountains.

Southern African mountains comprise those situated south of the Congo Rainforest and Lake Rukwa and include the mountainous islands of the western Indian Ocean. Thus, SAMC2025 is targeting Angola, the Comoros, the Democratic Republic of the Congo (southern mountains), Eswatini, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, La Réunion, South Africa, southern Tanzania, Zambia, and Zimbabwe.

The SAMC series is implemented by The Peaks Foundation (a non-profit company). SAMC2025 is held under the patronage of UNESCO.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept